Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 3 of 1012345...10...Last »

Bay State’s FORUM Pharma Lays Off 89 After Two Failed Clinical Trials

March 25, 2016 By Mark Terry, Breaking News Staff   Waltham, Mass.-based FORUM Pharmaceuticals, in light of two Phase III trial disappointments, is laying off half its staff and restructuring the company. In September 2015, the U.S. Food and Drug Administration (FDA) advised FORUM to halt its clinical trials of encenicline for Alzheimer’s disease. […]

Read More »

Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute

A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.   The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, […]

Read More »

Genetic study tracks start of Zika’s invasion of Americas back to 2013

The Zika virus currently sweeping through the Americas looks to have hitched a ride on a plane into Brazil in 2013 and begun its invasion of the continent from there, scientists said on Thursday.   In the first genome analysis of the current Zika epidemic, which has been linked in Brazil to cases of birth […]

Read More »

Many patients with high stroke risk do not get needed blood thinners

Patients who have a heart rhythm disorder that can come with a high risk of stroke often don’t receive blood-thinning medications that can make this complication less likely, a U.S. study suggests. Researchers studied almost 430,000 people with a condition known as atrial fibrillation, an irregular rapid heartbeat that can lead to stoke, heart failure […]

Read More »

Portola’s long-acting blood thinner misses main study goal

Portola Pharmaceuticals Inc said data showed its oral anticoagulant missed the main goal of preventing blood clots in acutely ill patients in a late-stage study. The company’s shares fell 30 percent to a two-year low of $20.00 in early trading. Portola’s betrixaban, designed for the prevention of venous thromboembolism (VTE), or blood clots, was tested […]

Read More »

U.S FDA issues draft guidance for abuse-deterrent opioid generics

The U.S. Food and Drug Administration issued draft guidance on Thursday for abuse-deterrent opioid generics, including a recommendation that studies be conducted to demonstrate that generic opioids are no less abuse-deterrent than branded drugs. The FDA said it was encouraging industry efforts to develop pain medicines that are more difficult to abuse. The regulator issued […]

Read More »

China says vaccine scandal suspect was free to re-offend

The person at the center of an illegal vaccine scandal in China had been sentenced for similar crimes but was allowed to re-offend after being given a suspended sentence, the head of a food and drug watchdog told a news conference on Thursday. The case involving a nearly $90 million black market vaccine ring has […]

Read More »

Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases

TARRYTOWN, N.Y., March 24, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer will jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and the vascular endothelial growth factor (VEGF) trap aflibercept, for the treatment of serious eye diseases. Two separate Phase 2 clinical studies are evaluating the combination therapy as a co-formulated […]

Read More »

Ex-Apple Exec Launches At-Home Blood Test Startup in San Francisco

March 24, 2016By Alex Keown, Breaking News Staff   SAN FRANCISCO – A former Apple (AAPL) executive who helped design the Apple Watch, has founded a blood-testing company that allows users to take their own blood samples and send the information to the cloud for analysis, Techcrunch reported. Bob Messerschmidt founded Cor and the […]

Read More »

Paul G. Allen Announces $100 Million to Launch the Paul G. Allen Frontiers Group

Initial commitment toward a larger 10-year plan will create group to explore and fund frontiers in bioscience   WASHINGTON, March 23, 2016 /PRNewswire-USNewswire/ — Philanthropist and entrepreneur Paul G. Allen today announced an initial commitment of $100 million to create The Paul G. Allen Frontiers Group, whose purpose will be to explore the landscape of […]

Read More »

PTC Therapeutics Chops 18% of Workforce

March 24, 2016By Alex Keown, Breaking News Staff   SOUTH PLAINFIELD, N.J. – Shares of PTC Therapeutics (PTCT) plunged in overnight trading Wednesday night after the company announced it was reducing its workforce by 18 percent following the rejection of its Duchenne muscular dystrophy (DMD) drug by the U.S. Food and Drug Administration. PTC […]

Read More »

Med Ad News Launches First-Ever MedAdvocate Judging Panel

The staff of Med Ad News implemented a new layer of judging to the 2016 Manny Awards creative categories process.

Read More »

Med Ad News Announces 2016 Manny Awards Finalists

Med Ad News Assembles MedAdvocates and Announces Finalists for the 2016 Manny Awards as well as Industry Person of the Year, Ed Mitzen of Fingerpaint.

Read More »

Respironics to settle U.S. kickback charges for $34.8 million

Respironics Inc. has agreed to pay $34.8 million to settle U.S. Department of Justice claims that it provided kickbacks in the form of free call center services to suppliers.

Read More »

E-COMMERCE: ITS Growth AND Long term Viewpoints

E-COMMERCE: ITS Growth AND Long term Viewpoints Business is identified as an activity of swapping services and goods in most cases for the money. Purchasers meet distributors to conduct the enterprise willingly. Marketers do sell off services and goods from manufacturers to clients immediately (sellers) or other stores (vendors).

Read More »

U.S. FDA approves Teva’s treatment for asthma

The U.S. FDA approved Teva Pharmaceutical Industries Ltd.’s drug to treat asthma in adults who have a history of severe attacks despite taking medication.

Read More »

AstraZeneca heart drug fails in key stroke trial

AstraZeneca’s heart drug Brilinta has failed to help stroke patients as hoped in a big clinical trial, dealing a blow to the company’s expectations that the medicine could rack up annual sales of $3.5 billion by 2023.   The trial found the blood-thinner was not significantly better than aspirin, the current standard of care, in […]

Read More »

Bristol-Myers Squibb to Acquire Padlock Therapeutics Inc.

 Gains full-rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program Expands Bristol-Myers Squibb’s immunoscience pipeline with potentially transformational approach to treating rheumatoid arthritis and other autoimmune diseases   March 23, 2016 06:59 AM Eastern Daylight Time   NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Padlock Therapeutics, Inc. announced today that the […]

Read More »

Merck patents on Hepatitis C treatment found valid in Gilead dispute

Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead’s blockbuster cure for hepatitis C.   After returning its verdict in favor of Merck on Tuesday, […]

Read More »

Sanofi, Regeneron unveil positive Praluent cholesterol study

French drugmaker Sanofi and U.S. partner Regeneron said a late-stage study of their Praluent injection showed it reduced the need for patients with an inherited form of high cholesterol to have bad cholesterol removed from their blood.   “This is the first time a PCSK9 inhibitor has shown in a clinical study that it reduced […]

Read More »

Page 3 of 1012345...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom